Autologous transplantation of CD133 selected hematopoietic progenitor cells for treatment of relapsed acute lymphoblastic leukemia

Barfield, Raymond; Hale, Gregory A.; Burnette, Ken; Behm, Frederick G.; Knapp, Katherine M.; Eldridge, Paul W.; Handgretinger, Rupert

doi:10.1002/pbc.20687

Cited by 17 publications

(10 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several approaches have been adopted to improve the quality of life and to increase the life expectancy of patients with hematological malignancies. Different methods of HSC therapy are found to be beneficial in leukemic patients [169-171]. …”

Section: Clinical Applications Of Hscmentioning

confidence: 99%

Plasticity and Maintenance of Hematopoietic Stem Cells During Development

Sugita

Pompili²,

Das

2011

BIOT

View full text Add to dashboard Cite

Maintenance of hematopoietic stem cells (HSCs) pool depends on fine balance between self-renewal and differentiation of HSCs. HSCs normally reside within the bone marrow niche of an adult mammal. The embryonic development of HSCs is a complex process that involves the migration of developing HSCs in multiple anatomical sites. Throughout the process, developing HSCs receive internal (transcriptional program) and external (HSC niche) signals, which direct them to maintain balance between self-renewal and differentiation, also to generate a pool of HSCs. In physiological condition HSCs differentiate into all mature cell types present in the blood. However, in pathological condition they may differentiate into non-hematological cells according to the need of the body. It was shown that HSCs can transdifferentiate into cell types that do not belong to the hematopoietic system suggests a complete paradigm shift of the hierarchical hematopoietic tree. This review describes the developmental origins and regulation of HSCs focusing on developmental signals that induce the adult hematopoietic stem cell program, as these informations are very critical for manipulating conditions for expansion of HSCs in ex vivo condition. This review also states clinical application and related patents using HSC.

show abstract

Section: Clinical Applications Of Hscmentioning

confidence: 99%

Plasticity and Maintenance of Hematopoietic Stem Cells During Development

Sugita

Pompili²,

Das

2011

BIOT

View full text Add to dashboard Cite

show abstract

“…1) [11,16,79,81,87,88,90]. More specifically, HSC transplants, alone or in combination therapy, may be used for the treatment of patients with autoimmune diseases, refractory and severe aplastic anemias, congenital thrombocytopenia, osteoporosis, cardiovascular disorders, chronic inflammatory Bowel disorders (IBD) including Crohn's disease and ulcerative colitis, diabetes mellitus, leukemias, multiple myelanomas and Hodgkin's and non-Hodgkin's lymphomas and aggressive tumors [1,2,11,16,[57][58][59][60][93][94][95][96][97]. It has also been reported that MSCs, EPCs and their progenies can contribute to the regenerative process of several tissues including bone, cartilage, tendon, muscle, adipose, brain, lung, heart, pancreas, kidney and eye [98,99].…”

Section: Therapeutic Applications Of Bm-derived Stem/progenitor Cellsmentioning

confidence: 99%

Recent Progress on Tissue-Resident Adult Stem Cell Biology and Their Therapeutic Implications

2008

View full text Add to dashboard Cite

Recent progress in the field of the stem cell research has given new hopes to treat and even cure diverse degenerative disorders and incurable diseases in human. Particularly, the identification of a rare population of adult stem cells in the most tissues/organs in human has emerged as an attractive source of multipotent stem/progenitor cells for cell replacement-based therapies and tissue engineering in regenerative medicine. The tissue-resident adult stem/progenitor cells offer the possibility to stimulate their in vivo differentiation or to use their ex vivo expanded progenies for cell replacement-based therapies with multiple applications in human. Among the human diseases that could be treated by the stem cell-based therapies, there are hematopoietic and immune disorders, multiple degenerative disorders, such as Parkinson's and Alzeimeher's diseases, type 1 or 2 diabetes mellitus as well as eye, liver, lung, skin and cardiovascular disorders and aggressive and metastatic cancers. In addition, the genetically-modified adult stem/progenitor cells could also be used as delivery system for expressing the therapeutic molecules in specific damaged areas of different tissues. Recent advances in cancer stem/progenitor cell research also offer the possibility to targeting these undifferentiated and malignant cells that provide critical functions in cancer initiation and progression and disease relapse for treating the patients diagnosed with the advanced and metastatic cancers which remain incurable in the clinics with the current therapies.

show abstract

“…Among them, there are leukemias, multiple myeloma, Hodgkin's and non- Hodgkin's lymphomas, melanoma and aggressive and metastatic solid tumors such as sarcomas, retinoblastoma, kidney, brain, lung, pancreatic, prostate, breast and ovarian cancers. 9-11,19,41,42 In fact, HSC transplant may restore the hematopoietic and immune systems after myeloablative effects induced by high-dose irradiation or chemotherapy following a treatment of cancer patients (Fig. 2).…”

Section: Bone Marrow-derived Stem/progenitor Cells and Their Therapeumentioning

confidence: 99%

“…For instance, the autologous transplantation of CD133 + selected HSCs may be used for pediatric patients with relapsed CD34 + /CD133 - leukemia. 42 The results from a recent investigation have also revealed that the homing and engraftment of BCR-ABL + leukemic stem cells (LSCs) in the BM of patients with chronic myelogenous leukemias (CMLs) is highly dependent on CD44 adhesion molecule expression in respect to normal HSCs. 46 Therefore, the targeting of CD44 LSC using an anti-CD44 antibody also may constitute an alternative approach for improving the efficacy of HSC transplantation in CML patients.…”

Section: Bone Marrow-derived Stem/progenitor Cells and Their Therapeumentioning

confidence: 99%

Great Promise of Tissue-Resident Adult Stem/Progenitor Cells in Transplantation and Cancer Therapies

Mimeault

Batra

2012

Advances in Experimental Medicine and Biology

View full text Add to dashboard Cite

Recent progress in tissue-resident adult stem/progenitor cell research has inspired great interest because these immature cells from your own body can act as potential, easily accessible cell sources for cell transplantation in regenerative medicine and cancer therapies. The use of adult stem/progenitor cells endowed with a high self-renewal ability and multilineage differentiation potential, which are able to regenerate all the mature cells in the tissues from their origin, offers great promise in replacing non-functioning or lost cells and regenerating diseased and damaged tissues. The presence of a small subpopulation of adult stem/progenitor cells in most tissues and organs provides the possibility of stimulating their in vivo differentiation, or of using their ex vivo expanded progenies for cell-replacement and gene therapies with multiple applications in humans without a high-risk of graft rejection and major side effects. Among the diseases that could be treated by adult stem cell-based therapies are hematopoietic and immune disorders, multiple degenerative disorders such as Parkinson's and Alzheimer's diseases, types 1 and 2 diabetes mellitus as well as skin, eye, liver, lung, tooth and cardiovascular disorders. In addition, a combination of the current cancer treatments with an adjuvant treatment consisting of an autologous or allogeneic adult stem/progenitor cell transplantation also represents a promising strategy for treating and even curing diverse aggressive, metastatic, recurrent and lethal cancers. In this chapter, we reviewed the most recent advancements on the characterization of phenotypic and functional properties of adult stem/progenitor cell types found in bone marrow, heart, brain and other tissues and discussed their therapeutic implications in the stem cell-based transplantation therapy.

show abstract

Autologous transplantation of CD133 selected hematopoietic progenitor cells for treatment of relapsed acute lymphoblastic leukemia

Cited by 17 publications

References 14 publications

Plasticity and Maintenance of Hematopoietic Stem Cells During Development

Plasticity and Maintenance of Hematopoietic Stem Cells During Development

Recent Progress on Tissue-Resident Adult Stem Cell Biology and Their Therapeutic Implications

Great Promise of Tissue-Resident Adult Stem/Progenitor Cells in Transplantation and Cancer Therapies

Contact Info

Product

Resources

About